Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine

NCT01928537 is registered in ClinicalTrials.gov with Traws Pharma, Inc. as lead sponsor.

NCT NCT01928537
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01928537 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine
Lead sponsor
Traws Pharma, Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2013
Completion date
June 29, 2017
Enrollment
67 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelomonocytic leukemia, cytopenia, myelodysplastic syndromes, refractory anemia with excess blasts